Aurobindo Pharma’s Unit VI, Cephalosporin oral formulations facility based in Hyderabad, India has received the Establishment Inspection Report (EIR) for the same. The Unit was re-inspected by US Food & Drug Administration (USFDA) in September 2012. This facility was re-inspected by USFDA subsequent to an import alert imposed in February 2011.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
